A recall of common blood pressure medication losartan has been expanded for a fifth time after manufacturer Torrent Pharmaceuticals found a possibly carcinogenic impurity in more batches of the ...

This covers lot No. JB8912 of Losartan Potassium Hydrochlorothiazide 100 mg or 25 mg tablets in 1,000-count bottles, expiration date 06/2020. None of the recalled tablets were distributed before ...

The affected Losartan Potassium tablets being recalled are described as: Losartan Potassium tablets, USP 25 mg, are light-green, film-coated, teardrop-shaped biconvex tablet with “LK 25” on ...

Konstam et al randomized 3846 patients in 30 countries who had NYHA class 2–4 heart failure, an LVEF <40%, and intolerance of ACE inhibitors to receive losartan at either 150 mg/day (n=1921 ...

Drug repackager Legacy Pharmaceutical Packaging is recalling 40 repackaged lots of Losartan Tablets USP 25 mg, 50 mg and 100 mg to the consumer level because they were made with an API in which ...

A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily ... accounting for approximately 40 percent of all cases in the United ...

Correction to: Hypertension Research (2014) 37, 1042–1049; doi:10.1038/hr.2014.114; published online 3 July 2014 The authors of the above paper noticed an error in ...